Join our mailing list
Sign up to receive regular updates from Retina UK and learn more about the most innovative research and technology news, upcoming events, fundraising and support services available.
Search
Search results
New ‘vision’ and identity sight loss charities
The collective partnership of eight of the leading charities in the sight loss sector, known for the last three years as the VI Charity Sector Partnership, has re-launched under a new identity of the ‘Vision Partnership’ with a re-invigorated purpose and new strategic focus.
New Chair of Trustees
We are delighted to welcome Kathy Evans as our new Chair of Trustees.
Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Potential drug targets identified for RP
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.
Genetic testing: an essential topic for discussion with the IRD community
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
Notice of the forthcoming Retina UK AGM – June 2023
Formal notice of the forthcoming Annual General Meeting in June 2023.
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Your donations make progress possible
Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments.
Light sensing small molecule given green light
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.